BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma
Our findings suggested that BIRC2 blockade facilitated immunotherapy of HCC by simultaneously sensitizing tumor cells to immune attack and boosting the anti-tumor immune response of T cells.
Authors
- Yansong Lin (ORCID: https://orcid.org/0000-0001-6095-4728)
- Jie Mei (ORCID: https://orcid.org/0000-0001-7799-8129)
- Lixuan Liu (ORCID: https://orcid.org/0000-0002-2781-9601)
- Ziteng Li (ORCID: https://orcid.org/0000-0001-9691-2589)
- Nai Li
- Lingyi Fu (ORCID: https://orcid.org/0000-0002-3519-3127)
- Chengyou Zheng
- Shuo Li (ORCID: https://orcid.org/0000-0002-9478-4285)
- Yuhua Huang (ORCID: https://orcid.org/0000-0002-0341-0078)
- Xia Yang (ORCID: https://orcid.org/0000-0003-1757-1355)
- Chao Cao (ORCID: https://orcid.org/0000-0002-0455-1171)
- Jing‐Ping Yun
- Liyun Huang
- Xiujiao Shen
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1186/s12943-025-02319-5
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University
- Sun Yat-sen University Cancer Center